Vanda Pharmaceuticals Reports First Quarter 2019 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. FIX
9. TSCO
10. BE

Go back to Vanda Pharmaceuticals Reports First Quarter 2019 Financial Results

Vanda Pharmaceuticals (VNDA) Misses Q1 EPS by 8c, Revenues Miss; Offers FY19 Revenue Outlook

May 1, 2019 4:11 PM EDT

Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q1 EPS of ($0.01), $0.08 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $47.71 million versus the consensus estimate of $51.74 million.

"During the first quarter, Vanda made significant advances towards its commercial and research goals. Patients on treatment with Hetlioz continue to increase steadily, driven by broader awareness and recognition of Non-24. We are preparing for a possible launch later this year in jet lag disorder, an indication... More